Clinical features and management of non-HIV-related lipodystrophy in children: A systematic review

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 2, 2017, Pages 363-374

  Gupta, Nidhi ^a   Asi, Noor ^a   Farah, Wigdan ^a   Almasri, Jehad ^a   Barrionuevo, Patricia ^a   Alsawas, Mouaz ^a   Wang, Zhen ^a   Haymond, Morey W ^b   Brown, Rebecca J ^c   Murad, M Hassan ^a  

^a MAYO CLINIC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FISH OIL; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; METRELEPTIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ACANTHOSIS NIGRICANS; ACQUIRED GENERALIZED LIPODYSTROPHY; ACROMEGALY; AMINOTRANSFERASE BLOOD LEVEL; APPETITE DISORDER; ASIAN; BLACK PERSON; BODY FAT; BONE AGE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONGENITAL GENERALIZED LIPODYSTROPHY; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; FAMILIAL PARTIAL LIPODYSTROPHY; GROWTH DISORDER; HEMOGLOBIN BLOOD LEVEL; HEPATOSPLENOMEGALY; HIRSUTISM; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LEPRECHAUNISM; LEPTIN DEFICIENCY; LIPODYSTROPHY; MENSTRUAL IRREGULARITY; MORTALITY; PANCREATITIS; PLASMAPHERESIS; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; CHILD; HIV ASSOCIATED LIPODYSTROPHY;

CHILD; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPODYSTROPHY; LIPODYSTROPHY, CONGENITAL GENERALIZED;

EID: 85012098055     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2271     Document Type: Review

References (69)

1. Garg A. Clinical review: Lipodystrophies: Genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313-3325.
2. Aotani D, Ebihara K, Sawamoto N, Kusakabe T, Aizawa-Abe M, Kataoka S, Sakai T, Iogawa H, Ebihara C, Fujikura J, Hosoda K, Fukuyama H, Nakao K. Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy. J Clin Endocrinol Metab. 2012;97(10):3663-3671.
3. Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy: Case reports and review of the literature. Medicine (Baltimore). 2003;82(2):129-146.
4. Misra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: Report of 35 cases and review of the literature. Medicine (Baltimore). 2004;83(1):18-34.
5. Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, Premkumar A, Depaoli AM, Skarulis MC, Oral EA, Gorden P. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism. 2004;53(4):513-519.
6. Muniyappa R, Brown RJ, Mari A, Joseph J, Warren MA, Cochran EK, Skarulis MC, Gorden P. Effects of leptin replacement therapy on pancreatic b-cell function in patients with lipodystrophy. Diabetes Care. 2014;37(4):1101-1107.
7. Simha V, Subramanyam L, Szczepaniak L, Quittner C, Adams- Huet B, Snell P, Garg A. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. J Clin Endocrinol Metab. 2012;97(3):785-792.
8. Bhayana S, Siu VM, Joubert GI, Clarson CL, Cao H, Hegele RA. Cardiomyopathy in congenital complete lipodystrophy. Clin Genet. 2002;61(4):283-287.
9. Boschmann M, Engeli S, Moro C, Luedtke A, Adams F, Gorzelniak K, Rahn G,Mähler A, Dobberstein K, Krüger A, Schmidt S, Spuler S, Luft FC, Smith SR, Schmidt HH, Jordan J. LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance. J Clin Endocrinol Metab. 2010;95(4):1634-1643.
10. Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: Comparison of baseline characteristics and response to metreleptin. J Clin Endocrinol Metab. 2015; 100(5):1802-1810.
11. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007;92(2):532-541.
12. Lupsa BC, Sachdev V, Lungu AO, Rosing DR, Gorden P. Cardiomyopathy in congenital and acquired generalized lipodystrophy: A clinical assessment. Medicine (Baltimore). 2010;89(4): 245-250.
13. Rother KI, Brown RJ. Novel forms of lipodystrophy: why should we care?. Diabetes Care. 2013;36(8):2142-2145.
14. Araujo-VilarD, Sánchez-Iglesias S, Guillín-Amarelle C, Castro A, Lage M, PazosM, Rial JM, Blasco J,Guillén-Navarro E, Domingo-Jiménez R, del CampoMR,González-Mendez B, Casanueva FF. Recombinant human leptin treatment in genetic lipodystrophic syndromes: The longterm Spanish experience. Endocrine. 2015;49(1):139-147.
15. Metwalley KA, Farghaly HS. Berardinelli-Seip syndrome type 1 in an Egyptian child. Indian J Hum Genet. 2014;20(1):75-78.
16. Dyment DA, Smith AC, Alcantara D, Schwartzentruber JA, Basel- Vanagaite L, Curry CJ, Temple IK, Reardon W, Mansour S, Haq MR, Gilbert R, Lehmann OJ, Vanstone MR, Beaulieu CL, Majewski J, Bulman DE, O'Driscoll M, Boycott KM, Innes AM; FORGE Canada Consortium. Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet. 2013;93(1):158-166.
17. Shastry S, Delgado MR, Dirik E, Turkmen M, Agarwal AK, Garg A. Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations. Am J Med Genet A. 2010;152A(9):2245-2253.
18. Kim CA, Delépine M, Boutet E, El Mourabit H, Le Lay S, Meier M, Nemani M, Bridel E, Leite CC, Bertola DR, Semple RK, O'Rahilly S, Dugail I, Capeau J, Lathrop M, Magré J. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab. 2008;93(4): 1129-1134.
19. Luo DQ, Wang XZ, Meng Y, He DY, Chen YM, Ke ZY, Yan M, Huang Y, Chen DF. Mandibuloacral dysplasia type A-associated progeria caused by homozygous LMNA mutation in a family from Southern China. BMC Pediatr. 2014;14:256.
20. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL, Dunger DB, Barford D, Umpleby AM, Wareham NJ, Davies HA, Schafer AJ, Stoffel M, O'Rahilly S, Barroso I. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science. 2004; 304(5675):1325-1328.
21. Kozusko K, Tsang VH, Bottomley W, Cho YH, Gandotra S, Mimmack M, Lim K, Isaac I, Patel S, Saudek V, O'Rahilly S, Srinivasan S, Greenfield JR, Barroso I, Campbell LV, Savage DB. Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy. Diabetes. 2015;64(1):299-310.
22. Miyoshi Y, Akagi M, Agarwal AK, Namba N, Kato-Nishimura K, Mohri I, Yamagata M, Nakajima S, Mushiake S, Shima M, Auchus RJ, Taniike M, Garg A, Ozono K. Severe mandibuloacral dysplasia caused by novel compound heterozygous ZMPSTE24 mutations in two Japanese siblings. Clin Genet. 2008;73(6):535-544.
23. Cardona-Hernández R, Suárez-Ortega L, Torres M. [Difficult to manage diabetes mellitus associated with generalized congenital lipodystrophy. Report of two cases]. An Pediatr (Barc). 2011;74(2): 126-130.
24. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO III, Gahl WA, Introne WJ. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008;358(6):592-604.
25. Agarwal AK, Fryns JP, Auchus RJ, Garg A. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet. 2003;12(16):1995-2001.
26. Donohue WL, Uchida I. Leprechaunism: A euphemism for a rare familial disorder. J Pediatr. 1954;45(5):505-519.
27. Brown RJ, Gorden P. Leptin therapy in patients with lipodystrophy and syndromic insulin resistance. In: Dagogo-Jack S, ed. Leptin: Regulation and Clinical Applications. Cham, Switzerland: Springer International Publishing; 2015:225-236.
28. Luedtke A, BoschmannM, Colpe C, Engeli S, Adams F, Birkenfeld AL, Haufe S, Rahn G, Luft FC, Schmidt HH, Jordan J. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: A case series. Horm Metab Res 2012;44: 306-311.
29. U.S. Food and Drug Administration. FDA approves Myalept to treat rare metabolic disease. [New release]. 2014. Available at: Http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm387060.htm. Accessed 15 April 2016.
30. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes. 2005;54(7):1994-2002.
31. Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care. 2003;26(1):30-35.
32. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346(8):570-578.
33. McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab. 2004;89(9):4258-4263.
34. Moon HS, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F, Paruthi J, Mantzoros CS. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013;34(3):377-412.
35. Handelsman Y, Oral EA, Bloomgarden ZT, Brown RJ, Chan JL, Einhorn D, Garber AJ, Garg A, Garvey WT, Grunberger G, Henry RR, Lavin N, Tapiador CD, Weyer C; American Association of Clinical Endocrinologists. The clinical approach to the detection of lipodystrophy-an AACE consensus statement. Endocr Pract. 2013;19(1):107-116.
36. Institute of Medicine of the National Academies. Clinical Practice Guidelines We Can Trust: Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs). 2011. Available at: Http:// www.nationalacademies.org/hmd//media/Files/Report%20Files/ 2011/Clinical-Practice-Guidelines-We-Can-Trust/Clinical%20Practice% 20Guidelines%202011%20Insert.pdf. Accessed 29 June 2016.
37. National Guideline Clearinghouse. Criteria for Inclusion of Clinical Practice Guidelines in NGC. 2016. Available at: Http://www. guideline.gov/about/inclusion-criteria.aspx. Accessed 29 June 2016.
38. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees P; Board of Trustees of the Guidelines International Network. Guidelines International Network: Toward international standards for clinical practice guidelines. Ann Intern Med. 2012; 156(7):525-531.
39. Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, Swiglo BA, Isley WL, Guyatt GH, Montori VM. Patient-important outcomes in registered diabetes trials. JAMA. 2008;299(21):2543-2549.
40. Huang HH, Chen TH, Hsiao HP, Huang CT, Wang CC, Shiau YH, Chao MC. A Taiwanese boy with congenital generalized lipodystrophy caused by homozygous Ile262fs mutation in the BSCL2 gene. Kaohsiung J Med Sci. 2010;26(11):615-620.
41. Garg A, Wilson R, Barnes R, Arioglu E, Zaidi Z, Gurakan F, Kocak N, O'Rahilly S, Taylor SI, Patel SB, Bowcock AM. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. J Clin Endocrinol Metab. 1999;84(9):3390-3394.
42. Magré J,DelépineM, Khallouf E, Gedde-Dahl T Jr, VanMaldergem L, Sobel E, Papp J, Meier M, Mégarbané A, Bachy A, Verloes A, d'Abronzo FH, Seemanova E, Assan R, Baudic N, Bourut C, Czernichow P, Huet F, Grigorescu F, de Kerdanet M, Lacombe D, Labrune P, Lanza M, Loret H, Matsuda F, Navarro J, Nivelon- ChevalierA, Polak M,Robert JJ, Tric P, Tubiana-RufiN,Vigouroux C, Weissenbach J, Savasta S,Maassen JA, Trygstad O, Bogalho P, Freitas P, Medina JL, Bonnicci F, Joffe BI, Loyson G, Panz VR, Raal FJ, O'Rahilly S, Stephenson T, Kahn CR, Lathrop M, Capeau J; BSCL WorkingGroup. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28(4):365-370.
43. Magré J, Delépine M, Van Maldergem L, Robert JJ, Maassen JA, Meier M, Panz VR, Kim CA, Tubiana-Rufi N, Czernichow P, Seemanova E, Buchanan CR, Lacombe D, Vigouroux C, Lascols O, Kahn CR, Capeau J, Lathrop M. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes. 2003;52(6): 1573-1578.
44. Leung DW. The structure and functions of human lysophosphatidic acid acyltransferases. Front Biosci. 2001;6:D944-D953.
45. Yang W, Thein S, Wang X, Bi X, Ericksen RE, Xu F, Han W. BSCL2/seipin regulates adipogenesis through actin cytoskeleton remodelling. Hum Mol Genet. 2014;23(2):502-513.
46. Agarwal AK, Garg A. Congenital generalized lipodystrophy: Significance of triglyceride biosynthetic pathways. Trends Endocrinol Metab. 2003;14(5):214-221.
47. Gomes KB, Pardini VC, Ferreira AC, Fernandes AP. Phenotypic heterogeneity in biochemical parameters correlates with mutations in AGPAT2 or Seipin genes among Berardinelli-Seip congenital lipodystrophy patients. J Inherit Metab Dis. 2005;28(6):1123-1131.
48. Davis J. Generalized lipodystrophy, infectious mononucleosis, mild infantile hemiplegia. Proc R Soc Med. 1954;47(2):128-129.
49. Hansen AE, McQuarrie I, Ziegler MR. Lipohistiodiaresis: A syndrome of lipodystrophy universalis, accelerated growth, lipemia, hepatic cirrhosis, and insulin-resistant diabetes without ketosis. J Lancet. 1961;81:533-541.
50. Billings JK, Milgraum SS, Gupta AK, Headington JT, Rasmussen JE. Lipoatrophic panniculitis: A possible autoimmune inflammatory disease of fat. Report of three cases. Arch Dermatol. 1987;123(12): 1662-1666.
51. Wesenberg RL, Gwinn JL, Barnes GR Jr. The roentgenographic findings in total lipodystrophy. Am J Roentgenol Radium Ther Nucl Med. 1968;103(1):154-164.
52. Eren E, Özkan TB, Çakir ED, Saǧlam H, TarimÖ. Acquired generalized lipodystrophy associated with autoimmune hepatitis and low serum C4 level. J Clin Res Pediatr Endocrinol. 2010;2(1):39-42.
53. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, Maillard S, Oliveira SK, Sztajnbok F, Cuttica R, Beltramelli M, Corona F, Katsicas MM, Russo R, Ferriani V, Burgos-Vargas R, Magni-Manzoni S, Solis-Valleoj E, Bandeira M, Zulian F, Baca V, Cortis E, Falcini F, Alessio M, Alpigiani MG, Gerloni V, Saad- Magalhaes C, Podda R, Silva CA, Lepore L, Felici E, Rossi F, Sala E, Martini A. Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63-72.
54. Simha V, Garg A. Phenotypic heterogeneity in body fat distribution in patients with congenital generalized lipodystrophy caused by mutations in the AGPAT2 or seipin genes. J Clin EndocrinolMetab. 2003;88(11):5433-5437.
55. Garg A, Fleckenstein JL, Peshock RM, Grundy SM. Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab. 1992;75(2):358-361.
56. Francis GA, Li G, Casey R, Wang J, Cao H, Leff T, Hegele RA. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med Genet. 2006;7:3.
57. Laudes M, Oberhauser F,Walgenbach K, Schubert M, Schulte DM, Faust M, Krone W. Comparison of phenotypes in male and female individuals of a new family with Dunnigan type of familial partial lipodystrophy due to a lamin A/C R482W mutation. Horm Metab Res 2009; 41:414-417.
58. Caldas D, Silva Júnior WS, Simonetti JP, Costa EV, Farias ML. [Biochemical, hormonal and genetic evaluation of the families of two Brazilian patients with type 2 familial partial lipodystrophy]. Arq Bras Endocrinol Metabol. 2013;57(8):583-593.
59. Araujo-VilarD, Loidi L,Dominguez F,Cabezas-Cerrato J. Phenotypic gender differences in subjects with familial partial lipodystrophy (Dunnigan variety) due to a nuclear lamin A/C R482Wmutation. Horm Metab Res 2003;35:29-35.
60. Schmidt HHJ, Genschel J, Baier P, Schmidt M, Ockenga J, Tietge UJF, Pröpsting M, Büttner C, Manns MP, Lochs H, Brabant G. Dyslipemia in familial partial lipodystrophy caused by an R482W mutation in theLMNAgene. J Clin Endocrinol Metab. 2001;86(5): 2289-2295.
61. Vantyghem MC, Faivre-Defrance F, Marcelli-Tourvieille S, Fermon C, Evrard A, Bourdelle-Hego MF, Vigouroux C, Defebvre L, Delemer B, Wemeau JL. Familial partial lipodystrophy due to the LMNA R482W mutation with multinodular goitre, extrapyramidal syndrome and primary hyperaldosteronism. Clin Endocrinol (Oxf). 2007;67(2):247-249.
62. Eisinger AJ, Shortland JR, Moorhead PJ. Renal disease in partial lipodystrophy. Q J Med. 1972;41(163):343-354.
63. Prasad NR,Reddy PA,Menon B, KarthikTS, Ahmed F,Chakravarthy M. Recurrent stroke as a presenting feature of acquired partial lipodystrophy. Indian J Endocrinol Metab. 2012;16(Suppl 2): S455-S457.
64. Murad MH, Montori VM, Ioannidis JP, Jaeschke R, Devereaux PJ, Prasad K, Neumann I, Carrasco-Labra A, Agoritsas T, Hatala R, Meade MO,Wyer P, Cook DJ, Guyatt G. How to read a systematic review and meta-analysis and apply the results to patient care: Users' guides to the medical literature. JAMA. 2014;312(2):171-179.
65. Licinio J, Negrao AB, Wong ML. Plasma leptin concentrations are highly correlated to emotional states throughout the day. Transl Psychiatry. 2014;4:e475.
66. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: The role of leptin in human physiology: Emerging clinical applications. Ann Intern Med. 2010;152(2):93-100.
67. Kazmi A, Sattar A, Hashim R, Khan SP, Younus M, Khan FA. Serum leptin values in the healthy obese and non-obese subjects of Rawalpindi. J Pak Med Assoc. 2013;63(2):245-248.
68. Erhardt E, Foraita R, Pigeot I, Barba G, Veidebaum T, Tornaritis M, Michels N, Eiben G, Ahrens W, Moreno LA, Kovács E, Molnár D; IDEFICS Consortium. Reference values for leptin and adiponectin in children below the age of 10 based on the IDEFICS cohort. Int J Obes. 2014;38(Suppl 2):S32-S38.
69. Zhou X, Chai Y, Chen K, Yang Y, Liu Z. A meta-analysis of reference values of leptin concentration in healthy postmenopausal women. PLoS One. 2013;8(8):e72734.